Does hpv vaccine really prevent cervical cancer?

The HPV vaccine prevents precancerous lesions caused by the targeted virus types, but the evidence that it has reduced actual cervical cancer rates in vaccinated populations is surprisingly thin.

The key question is whether fewer vaccinated women are dying of cervical cancer. The retrieved evidence does not contain a single study that directly measures cervical cancer incidence or mortality in a vaccinated group against a true unvaccinated control group. What exists are trials that used surrogate endpoints: precancerous lesions called CIN2/3 [5, 6]. The manufacturer-funded FUTURE trials showed near-perfect efficacy against these lesions in women who had never been exposed to HPV [7]. That is a real finding, but a surrogate is not the same as cancer. Most CIN2 lesions regress on their own, and the progression rate from high-grade CIN to invasive cancer is only about 12% [2].

Meanwhile, population-level data raises questions. A 2025 Canadian study found that cervical cancer incidence has been rising in women aged 35-54 from 2001 to 2022, despite the HPV vaccination program [1]. A 2026 U.S. study showed the overall decline in invasive cervical cancer slowed sharply after 2011, and the proportion of women diagnosed at stage IV (the deadliest) actually increased from 10.1% to 15.5% [4]. These are ecological observations, not proof of vaccine failure, but they are the opposite of what a successful cancer-prevention program should look like.

The mechanism is also incomplete. The vaccines target only HPV 16 and 18, which cause about 73% of cervical cancers [2]. The remaining 27% come from other high-risk types. A 2012 modeling study predicted that vaccinating against the targeted types could cause an apparent 3-10% increase in cancers from non-vaccine types, a phenomenon called "unmasking" [3]. The 9-valent vaccine covers more types but still not all, and no long-term safety data exists for any of them beyond a few years of follow-up [7].

My call: the HPV vaccine prevents surrogate lesions in controlled trials, but the claim that it "prevents cervical cancer" in the real world is not proven by the evidence retrieved here. Confidence: low that the vaccine has meaningfully reduced population-level cervical cancer rates.